Pharmamarketeer
wet- en regelgeving

AstraZeneca’s Lynparza scores limited NICE backing for new first-line maintenance use

29 juli 2019
FiercePharma

With competitors racking up new indications and data wins, AstraZeneca’s Lynparza is looking to keep its lead in the PARP inhibitor field. England’s cost watchdog delivered a leg up Friday with a new recommendation—a couple caveats notwithstanding.

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)